Supporting Investigator-Initiated Clinical Trials to Deliver Promising Treatments Sooner
In 2002, Japan’s Pharmaceutical Affairs Law (now known as the Pharmaceuticals and Medical Devices Act) was revised, making it possible for physicians to conduct investigator-initiated clinical trials (IITs). This regulatory change opened the door to developing treatments in areas where pharmaceutical companies may find it challenging to take the lead—such as rare diseases with very few patients or fields where academic research is already far advanced.
However, IITs place a significant burden on the principal investigator, as the physician must independently plan and manage the trial. Despite ongoing improvements in regulatory frameworks and the establishment of institutional support systems at universities and hospitals, conducting IITs remains a complex and demanding endeavor.
At FiveRings, we are committed to supporting investigator-initiated trials with the hope of accelerating the delivery of effective therapies to patients in need. With the shared dream of bringing new treatments to the bedside of those suffering from illness, our dedicated team works together to make this vision a reality.